Continually Updated Clinical Reference
 
 
  All Sources     eMedicine     Medscape     Drug Reference     MEDLINE
 
You are in: eMedicine Specialties > Emergency Medicine > Toxicology

Toxicity, Methamphetamine

Last Updated: July 12, 2006
Email to a Colleague
Synonyms and related keywords: amphetamine, ice, crystal, meth, crystal meth, methamphetamine use, stimulant, euphoria, methamphetamine-intoxication, speedballing, myocardial infarction, palpitations, agitation, anxiety, hallucinations, amphetamine-induced seizures, emotional lability, confusion, paranoia, suicidal ideation, delusions, despondent affect, drug-induced psychosis, acute toxic psychosis, methamphetamine-induced seizures, hyperthermia, coma, muscle hyperactivity, metabolic acidosis, secondary rhabdomyolysis, renal failure, shock, lichenoid drug eruption, tachycardia, hypertension, atrial arrhythmias, ventricular arrhythmias, myocardial ischemia, atherosclerosis, severe orthostatic hypotension, acute cardiomyopathy, chronic cardiomyopathy, cardiac toxicity, amphetamine-induced hypertension, necrotizing angiitis, arterial aneurysms, arterial sacculations, acute aortic dissections, bacterial endocarditis, fungal endocarditis, abnormal cardiac valves, secondary dilated cardiomyopathy, septic embolism, mycotic aneurysm, seizures, psychosis, choreoathetoid movement disorders, cerebrovascular accidents, cerebral edema, cerebral vasculitis, coma, clonus, respiratory failure, spontaneous cerebral hemorrhaging, amphetamine-induced cerebral vasculitis, cerebral artery spasm, cerebral artery occlusion, ischemic strokes, transient cortical blindness, pneumomediastinum, pneumothorax, pneumopericardium, acute noncardiogenic pulmonary edema, pulmonary hypertension, hypoxemia, rhabdomyolysis, cardiovascular shock, acute tubular necrosis, renal necrotizing angiitis, amphetamine-induced acute interstitial nephritis, hepatocellular damage, giant GI ulcers, ischemic colitis, smoking methamphetamine HCl powder

  AUTHOR INFORMATION Section 1 of 10    Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Author: Robert Derlet, MD, Professor of Emergency Medicine, University of California at Davis School of Medicine; Chief, Division of Emergency Medicine, UC Davis Health System

Coauthor(s): Timothy Albertson, MD, PhD, Vice-Chair of Clinical Affairs, Chief, Professor of Anesthesiology, Medical Pharmacology and Toxicology, Departments of Internal Medicine and Anesthesiology, University of California at Davis Medical Center

Robert Derlet, MD, is a member of the following medical societies: American Academy of Emergency Medicine, American Association for the Advancement of Science, Infectious Diseases Society of America, Society for Academic Emergency Medicine, and Wilderness Medical Society

Editor(s): Edward A Michelson, MD, Program Director, Associate Professor, Department of Emergency Medicine, University Hospital Health Systems in Cleveland; John T VanDeVoort, PharmD, Clinical Assistant Professor, College of Pharmacy, University of Minnesota; Fred Harchelroad, MD, FACMT, Chair, Department of Emergency Medicine, Director of Medical Toxicology, Associate Professor, Department of Emergency Medicine, Allegheny General Hospital; John Halamka, MD, Chief Information Officer, CareGroup Healthcare System, Assistant Professor of Medicine, Department of Emergency Medicine, Beth Israel Deaconess Medical Center; Assistant Professor of Medicine, Harvard Medical School; and Asim Tarabar, MD, Assistant Clinical Professor of Emergency Medicine, Yale University School of Medicine; Consulting Staff, Department of Emergency Medicine, Yale-New Haven Hospital

Disclosure


  INTRODUCTION Section 2 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Background: Methamphetamine use has increased rapidly in the United States and now involves all regions of the country.

Methamphetamine and related compounds can produce euphoria and stimulant effects. In addition, it may generate many of the same toxic effects seen with other stimulants such as cocaine. The ease of synthesis from inexpensive and readily obtainable chemicals has led to the widespread and rampant increase in abuse of this dangerous drug. Many US emergency departments (EDs) now treat as many methamphetamine-intoxicated patients as cocaine-intoxicated patients.

The euphoria produced by methamphetamine appears similar to that produced by cocaine. Methamphetamine may be taken orally, intravenously, or in a smokable form. Patients who inhale the smokable form of methamphetamine (ie, ice) experience an immediate euphoria similar to that of crack cocaine, but the effects may last much longer.

Individuals who abuse methamphetamine range widely in age, socioeconomic status, and ethnic background. Recently, epidemic abuse has been described in some groups of adolescents; they cite availability, low cost, and a longer duration of action than cocaine as reasons for their drug preference.

The medical history of amphetaminelike compounds extends back nearly 100 years. A Japanese pharmacologist first synthesized methamphetamine in 1919. A more detailed analysis of the pharmacology of amphetamine derived from the basic phenylethylamine structure was reported in 1930. Amphetamine was introduced in the 1930s in the form of inhalers for treating rhinitis and asthma. The stimulant, euphoric, and anorectic effects of amphetamine were recognized quickly, leading to its abuse. In 1937, a report stating that amphetamine could enhance intellectual performance through enhanced wakefulness further contributed to the popularity and early abuse of amphetamine. Amphetamines were used extensively by Allied and Axis armed forces during World War II and during the 1991 Operation Desert Storm, allegedly to increase wakefulness and attention. Recreational abuse of amphetamine has been used to achieve a euphoric state.

Initial federal controls were enacted in the late 1950s, but amphetamine continued to be abused by students, athletes, shift workers, truck drivers, and others into the next decade. The Controlled Substance Act of 1970 stringently regulated the manufacture of amphetamine. Despite the decline of industrially synthesized amphetamines, illicit methamphetamine use continues to increase.

Pathophysiology: Amphetamines stimulate the central nervous system (CNS), which results in one or more clinical effects: inducing euphoria; intensifying emotions; altering self-esteem; and increasing alertness, aggression, and sexual appetite.

In the brain, presynaptic reuptake of catecholamines (ie, dopamine, norepinephrine) is blocked, causing hyperstimulation at selected postsynaptic neuron receptors. Indirect sympathomimetic effects of amphetamines are also caused by blocking presynaptic vesicular storage and by reducing cytoplastic destruction of catecholamines by inhibiting mitochondrial monoamine oxidase. Indirectly, these hyperstimulated neurons can stimulate various other noncatecholaminergic central and peripheral nervous pathways. Sympathomimetic stimulation of central and peripheral pathways by most amphetamines may occur directly but to a much lesser extent than with ephedrine.

Changes in mood, excitation, motor movements, sensory perception, and appetite appear to be mediated more directly by central dopaminergic alterations. It has been postulated that serotonin alterations contribute to the amphetamine-related mood changes, psychotic behavior, and aggressiveness.

In humans, the half-life of methamphetamine ranges from 10-20 hours, depending on the urine pH (half-life is shorter in acidic urine), history of recent use, and dosage. Methamphetamine has greater CNS effects compared to D-amphetamine, presumably because of the prolonged half-life and increased CNS penetration. A significant portion of methamphetamine is metabolized to amphetamine.

Methamphetamine is absorbed readily from the gut, airway, nasopharynx, muscle, placenta, and vagina. Peak plasma levels are observed approximately 30 minutes after IV or IM routes and 2-3 hours postingestion. Rapid tissue redistribution occurs with steady-state cerebrospinal fluid levels of about 80% of plasma levels. Hepatic conjugation pathways with glucuronide and glycine additions can result in inactivation and urine excretion of amphetamine metabolites.

When methamphetamine is used with ethanol, increased psychological and cardiac effects are observed. This is presumed to be the result of pharmacodynamic rather than pharmacokinetic interactions. Similarly, the increased toxicity of simultaneously used opioids and amphetamines, such as methamphetamine (ie, speedballing), appear to result from pharmacodynamic interactions.

The euphoric effects produced by methamphetamine, cocaine, and various designer amphetamines are similar and may be difficult to clinically differentiate. A distinguishing clinical feature is the longer pharmacokinetic and pharmacodynamic half-life of methamphetamine, which may be as much as 10 times longer than the half-life of cocaine.

Animal studies with D-amphetamine and cocaine suggest that some differences in underlying mechanisms of toxicity may exist between these agents. Because of the variability in quality and concentration of illicitly purchased methamphetamines, the clinical observation of toxic effects usually is more relevant than an estimate of total ingested dose. Although hair and saliva analysis have been reported, most toxicological monitoring or testing is performed with urine and blood samples.

Frequency:

  • In the US: Widespread

Race: No scientific data have found that outcomes of methamphetamine exposure are dependent on race.

Sex: No scientific data have found that outcomes of methamphetamine exposure are dependent on sex.


  CLINICAL Section 3 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

History: Clinical toxicity of amphetamines and related compounds primarily affect the cardiovascular and central nervous systems. Patients may present with pulmonary symptoms if the drugs are inhaled or smoked.

  • Cardiovascular signs include the following:
    • Chest pain, ischemia, or myocardial infarction
    • Tachycardia and/or palpitations
  • Central nervous system signs include the following:
    • Agitation, anxiety, and hallucinations are typical complaints.
    • Some patients who have used methamphetamine present unconscious to the ED. In these persons, lack of responsiveness may be partially caused by use of other drugs (ie, opioids).
    • Other patients may be unresponsive because of the direct effects of intravenous methamphetamine use or secondary to amphetamine-induced seizures.
    • The initial feeling of physical and mental enhancement following amphetamine use can quickly deteriorate with high doses or chronic use, resulting in emotional lability, confusion, paranoia, and hallucinations.
    • Altered mental status was found in 57% of a series of 127 amphetamine-toxic patients who presented to an ED with agitation, suicidal ideation, hallucinations, delusions, confusion, and despondent affect. These are the most common major signs and symptoms of amphetamine abuse. Patients challenged with large doses of intravenous methamphetamine developed drug-induced psychosis if they were dependent on amphetamine but not if they were naive.
    • Methamphetamine can induce an acute toxic psychosis in previously healthy persons and precipitate a psychotic episode in those with psychiatric illness.
    • Methamphetamine-induced seizures have been viewed as isolated events or associated with hyperthermia, coma, muscle hyperactivity, metabolic acidosis, secondary rhabdomyolysis, renal failure, and shock.
  • Respiratory signs include the following:
    • Dyspnea
    • Wheezing
  • Increases and decreases in sexual desire and activity have been reported with amphetamine use.
  • Methamphetamine use and/or abuse during pregnancy can be fatal to the mother and result in spontaneous abortion or teratogenesis to the fetus. Methamphetamine has been shown to cause placental vasoconstriction and interfere with placental monoamine transporters.
  • Although not formally studied, the most common dermatological manifestations in patients who abuse amphetamine-related compounds are probably related to self-induced skin picking, intravenous needles, or burns.
  • A case of lichenoid drug eruption has been reported with the use of methamphetamine.

Physical:

  • Cardiovascular
    • Tachycardia and hypertension may be observed.
    • Atrial and ventricular arrhythmias and myocardial ischemia have been noted.
    • Chest pain, associated with cardiac ischemia, following methamphetamine use may occur. Patients are at risk for cardiac ischemia because of accelerated atherosclerosis from chronic drug use and other less well-understood mechanisms. Concern that thrombus formation may be contributing to amphetamine-related myocardial infarction has generated at least one case report on the use of thrombolytics, in addition to the use of nitrates and analgesics, in patients with chronic drug use.
    • Significant hypotension with bradycardia and metabolic acidosis has been observed in massive amphetamine overdoses.
    • Suppression of vasomotor outflow leading to severe orthostatic hypotension because of amphetamine intoxication also has been reported. This suggests that multiple mechanisms contribute to the development of circulatory collapse with amphetamine abuse.
    • Acute and chronic cardiomyopathy is thought to be secondary to direct amphetamine cardiac toxicity and indirectly from amphetamine-induced hypertension, necrosis, and ischemia. Although most reports of cardiomyopathy have implicated oral and intravenous amphetamines as causes, smoking of methamphetamine has also been documented as a cause.
    • Necrotizing angiitis with arterial aneurysms and sacculations have been observed in the kidney, liver, pancreas, and small bowel of methamphetamine drug abusers.
    • Similarly, acute aortic dissections and arterial aneurysms have been associated with methamphetamine abuse.
    • With the illicit use of any intravenous drug, bacterial or fungal endocarditis can lead to abnormal cardiac valves, secondary dilated cardiomyopathy, septic embolism, and mycotic aneurysm. Recently, some individuals orally taking fenfluramine and phentermine for appetite suppression have been found to have valvular abnormalities leading to mitral and aortic regurgitation.
  • Central nervous system
    • Seizures and psychosis may occur.
    • Acute and chronic amphetamine exposures have also been associated with choreoathetoid movement disorders independent of Huntington disease.
    • Other CNS disorders induced by amphetamines include cerebrovascular accidents caused by hemorrhage or vasospasm, cerebral edema, and cerebral vasculitis. Coma, clonus, and respiratory failure are characterized in a recent report of massive dexfenfluramine overdose.
    • Spontaneous cerebral hemorrhaging has been reported in patients using amphetamines, as well as in patients with preexisting arteriovenous malformations and with amphetamine-induced cerebral vasculitis.
    • Cerebral artery spasm and occlusion, leading to ischemic strokes and transient cortical blindness, have been noted following methamphetamine use.
  • Respiratory
    • Barotrauma, including pneumomediastinum, pneumothorax, and pneumopericardium

    • Acute noncardiogenic pulmonary edema

    • Pulmonary hypertension
    • Renal and hepatic

      • Renal failure associated with amphetamines has been related to hypoxemia, rhabdomyolysis, necrotizing angiitis, and cardiovascular shock with subsequent acute tubular necrosis.

      • Renal necrotizing angiitis, noted in some cases of renal failure, has been observed in the presence of hepatitis B serum antigen and is usually found in those who use intravenous amphetamines.

      • In one case report, amphetamine-induced acute interstitial nephritis was thought to be the cause of renal failure.
    • Hepatocellular damage has been reported with amphetamine, malondialdehyde (MDA), and 3,4-methylelenedioxy-methamphetamine (MDMA) after acute and chronic abuse. Direct toxic effects (eg, hypotension, hepatotoxic, contaminants, hepatic vasoconstriction, lipid peroxidation, occult viral causes, necrotizing angiitis) have been postulated as mechanisms for amphetamine-induced hepatocellular toxicity.

    • Abuse of methamphetamine has also been associated with the formation of giant GI ulcers and ischemic colitis.

Causes:

  • Illicit production of methamphetamine
    • Methamphetamine is relatively easy to synthesize, and illicit production occurs in home kitchens, workshops, recreational vehicles, and rural cabins.
    • Methamphetamine is a derivative of phenylethylamine. The substances differ structurally in that a methyl group attaches to the terminal nitrogen to form methamphetamine.
    • The federal government and some states have enacted laws decreasing the availability of necessary precursor chemicals. Many of these agents can still be obtained in neighboring states or countries.
  • Synthesis
    • A common method of synthesis begins with L-ephedrine, which is reduced to methamphetamine using hydriodic acid and red phosphorus.
    • Alternative approaches include using a different acid, a different catalyst, or a substituted ephedrine (eg, chloroephedrine, methylephedrine).
  • The methamphetamine produced by ephedrine reduction is a lipid-soluble pure base form, which is fairly volatile and can evaporate if left exposed to room air temperature. This product is converted to the water-soluble form, methamphetamine hydrochloride (HCl) salt.
    • Illicitly synthesized methamphetamine may be contaminated by nonstimulant organic or inorganic impurities. Poisoning from heavy metals, such as lead and mercury, or from solvents used in the synthesis process have been reported. Exposures to carcinogenic materials have been noted.
    • Street methamphetamine may be mixed with many drugs, including cocaine. Studies show that 8-20% of street-available stimulants contain both drugs. In a report on cocaine intoxication, 7% of patients sought medical help because of concurrent use of cocaine and amphetamines.
    • Fatalities related to amphetamine use have been associated with assaults, suicides, homicides, accidents, driving impairment, and maternal-fetal and infant exposures
    • In 1987, approximately one eighth of all homicides in San Diego County involved methamphetamine.
    • In a recent study of drug abuse and alcohol consumption related to motor vehicle accidents in Belgium, amphetamine was the most commonly found drug other than alcohol. A study of 28 drivers arrested or killed in traffic accidents with blood samples positive for methamphetamine showed that typical driving behaviors include aggressive and erratic driving with high-speed collisions.
    • Making ice, the smokable form of methamphetamine, from standard quality methamphetamine HCl is essentially a purification process. Methamphetamine HCl is added slowly to water that has been heated 80-100°C until a supersaturated solution is obtained. When the slurry is cooled, pure HCl salt of methamphetamine (ice) precipitates. Methamphetamine HCl, unlike cocaine HCl, is volatile and can be smoked. Other solvents, such as isopropanol, have been used in place of water to speed the process. Uncontrolled variations of this process can result in unreliable removal or addition of impurities. The physical characteristics of the final product depend on the quality and type of reagents used and on contaminants that may have been introduced. The lack of significant further processing of methamphetamine HCl has resulted in increased availability and popularity of smoking the drug.
    • One reason for the popularity of smoked methamphetamine is the immediate clinical euphoria that results from the rapid absorption in the lungs and deposition in the brain.
    • Smoking methamphetamine HCl powder, crystals, or ice occurs first by placing the substance into a piece of aluminum foil that has been molded into the shape of a bowl, a glass pipe, or a modified light bulb and heating it over the flame of a cigarette lighter or torch. Then, the volatile methamphetamine fumes are inhaled through a straw or pipe.
  DIFFERENTIALS Section 4 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Acute Respiratory Distress Syndrome
Headache, Migraine
Hypertensive Emergencies
Hyperthyroidism, Thyroid Storm, and Graves Disease
Myocardial Infarction
Myocarditis
Pediatrics, Febrile Seizures
Pediatrics, Tachycardia
Status Epilepticus
Toxicity, Amphetamine
Toxicity, Anticholinergic
Toxicity, Antihistamine
Toxicity, Hallucinogen
Toxicity, Mushroom - Hallucinogens
Toxicity, Sympathomimetic
Toxicity, Theophylline


Quick Find
Author Information
Introduction
Clinical
Differentials
Workup
Treatment
Medication
Follow-up
Miscellaneous
Bibliography

Click for related images.

Related Articles
Acute Respiratory Distress Syndrome

Headache, Migraine

Hypertensive Emergencies

Hyperthyroidism, Thyroid Storm, and Graves Disease

Myocardial Infarction

Myocarditis

Pediatrics, Febrile Seizures

Pediatrics, Tachycardia

Status Epilepticus

Toxicity, Amphetamine

Toxicity, Anticholinergic

Toxicity, Antihistamine

Toxicity, Hallucinogen

Toxicity, Mushroom - Hallucinogens

Toxicity, Sympathomimetic

Toxicity, Theophylline


Patient Education



  WORKUP Section 5 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Lab Studies:

  • Perform laboratory studies based on the patient's symptoms.
  • Obtain a baseline complete blood count (CBC) and chemistry panel for all patients.
  • Measure creatinine kinase (CK) and myoglobin levels to exclude rhabdomyolysis that may be present despite minimal symptoms. Obtain myocardial band enzymes of CK (CK-MB) and a troponin level if concern of myocardial ischemia from methamphetamine use exists.
  • Perform pregnancy tests in women of childbearing age.

Imaging Studies:

  • Order a chest radiograph for patients with pulmonary symptoms or chest trauma.
  • In patients with altered mental status, perform a head CT scan to exclude intracranial bleeding. Such bleeding may be the result of either methamphetamine-induced hypertension or associated head trauma.

Other Tests:

  • Obtain an ECG for all patients.
  • Patients with symptomatic chest pain should have myocardial infarction excluded using standard rule-out protocol.
  • Obtain serial ECGs, CK isoenzymes, myoglobin, and troponin (T or I) at the appropriate intervals.
  TREATMENT Section 6 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Prehospital Care: Patients with acute methamphetamine intoxication may be highly agitated and present a serious safety risk to prehospital personnel. Seek additional help from police or other EMS providers before patient transport, if possible. Prehospital IV access is warranted with patient consent, allowing for treatment of seizures and agitation using IV benzodiazepines according to medical direction or protocol.

Patient mental function may be sufficiently impaired, precluding the patient from making an informed decision to refuse treatment and transport.

Emergency Department Care: Most cases of amphetamine toxicity can be managed supportively. In the case of a severe overdose, immediate supportive care, including airway control, oxygenation and ventilation support, and appropriate monitoring is required. Specific treatments for heavy metal toxicity caused by contaminants in some methamphetamine preparations may be needed. Animal studies suggest that orally ingested but not IV amphetaminelike compounds can be decontaminated with oral activated charcoal. In severe overdoses, termination of amphetamine-induced seizure activity and arrhythmias are of immediate importance. Correction of hypertension, hypotension, hyperthermia, metabolic and electrolyte abnormalities, and control of severe psychiatric agitation are indicated. Consider health maintenance activities, such as testing for hepatitis and HIV disease.

  • Agitation
    • Because of the ability of methamphetamine to cause significant CNS and psychiatric activation, patients who present to EDs for acute intoxication may require pharmacologic intervention.
    • Diazepam, a benzodiazepine that enhances GABA neurotransmission (probably nonspecifically), affects methamphetamine-induced behavioral and psychiatric intoxication. It is also used to terminate amphetamine-induced seizures.
    • Diazepam was found to be highly effective in antagonizing the toxic effects of cocaine but not as effective against amphetamines in animal models. In a recent study of 146 patients presenting to the ED agitated, violent, or psychotic from methamphetamine, droperidol produced more rapid and profound sedation than lorazepam. Droperidol and lorazepam produced clinically significant reductions in pulse, systolic blood pressure, respiration rate, and temperature over a 60-minute period.
    • Significant social and psychiatric intervention is needed to reduce long-term dependency on amphetamines.
  • Hypertension

  • If sedation fails, several antihypertensive agents, including short-acting IV beta-blockers or direct short-acting vasodilators, are effective in reversing some methamphetamine-induced hypertension.

  • Theoretically, IV labetalol would be the best agent because of combined anti–alpha-adrenergic and anti–beta-adrenergic effects. However, when given IV, labetalol loses much of its anti–alpha-adrenergic effect.

  • These drugs should be given in small IV doses and titrated to effect. However, clinical experience has shown labetalol and esmolol to be equally effective.

  • In rare instances, agents such as nitroprusside or fenoldopam are necessary.
  • Myocardial infarction

    • The approach to the patient with methamphetamine-induced cardiac ischemia should be no different than in other cases. Nitrates, thrombolytics, beta-blockers, and other commonly used agents can also be used in the case of methamphetamine toxicity.

    • Carefully monitor blood pressure to ensure that it does not exceed contraindicated levels for thrombolytics.

    • Beta-blockers are very helpful in reducing oxygen demand because most patients have significant tachycardia.
  • Seizures

    • Treat methamphetamine-induced seizures like other seizures of unknown etiology.

    • Administer benzodiazepines IV (see Medication).

    • In those patients who do not have IV access, an agent that has good IM absorption can be used (eg, lorazepam, midazolam).

    • After control of the acute episode, administer longer-acting stabilizing agents, such as phenobarbital.

    • All patients with methamphetamine-induced seizures are at high risk for intracranial bleeding and should receive a head CT scan as soon as possible.
  • Rhabdomyolysis

  • Suspect rhabdomyolysis, and rule it out by drawing initial CK levels in patients who present to the ED with severe agitation from amphetamines.

  • Aggressively treat patients with rhabdomyolysis with fluids and admit them to the hospital.

  • Closely monitor renal function, vital signs, and fluid input and output.

  • Early and aggressive fluid and electrolyte treatment of potential rhabdomyolysis can improve the clinical outcome and decrease potential nephrotoxicity.

Consultations: Consult with a regional poison control center or a local medical toxicologist (certified through the American Board of Medical Toxicology and/or the American Board of Emergency Medicine) to obtain additional information and patient care recommendations.
  MEDICATION Section 7 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

The goals of pharmacotherapy are to reduce the toxic effects of the drug, reduce morbidity, and prevent complications.

Drug Category: GI decontaminant -- Empirically used to minimize systemic absorption of the toxin.
Drug Name
Activated charcoal (Liqui-Char) -- Most useful if administered within 4 h of ingestion. Repeat doses may be used, especially with ingestion of sustained release agents. Limited outcome studies exist, especially when administration is more than 1 h postingestion.
Administration of charcoal by itself (in aqueous solution), as opposed to coadministration with a cathartic, is becoming the current practice standard. This is because studies have not shown benefit from cathartics, and, while most drugs and toxins are absorbed within 30-90 min, laxatives take hours to work. Dangerous fluid and electrolyte shifts have occurred when cathartics are used in small children.
When ingested dose is known, charcoal may be administered at 10 times ingested dose of agent over 1 or 2 doses.
Adult Dose1 g/kg PO/NG (50-75 g usual dose); may administer 0.5 g/kg PO/NG as repeat dose if desired
Cathartic not recommended
Pediatric DoseAdminister as in adults (12.5-25 g usual dose); cathartic not recommended
ContraindicationsDocumented hypersensitivity; poisoning or overdose of mineral acids and alkalies; unprotected airway with absent gag reflex
Interactions May inactivate ipecac syrup if used concomitantly; effectiveness of other medications decreases with coadministration; decreased levels occur when administered with sherbet, milk, or ice cream
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsProtect airway before administration in patients with absent gag reflex or a depressed level of consciousness; when considering repeat dosing, monitor for active bowel sounds to minimize risk of charcoal ileus
Drug Category: Benzodiazepines and other sedatives -- By increasing the action of GABA, which is a major inhibitory neurotransmitter in the brain, benzodiazepines depress all levels of CNS, including limbic and reticular formation. Neuroleptic agents are useful for control of severely disturbed and/or violent patients.
Drug Name
Haloperidol (Haldol) -- DOC for patients with acute psychosis when no contraindications are present. Parenteral dosage form may be admixed in syringe with 2-mg lorazepam for better anxiolytic effects. May be administered IM if unable to establish IV access.
Adult Dose2.5 mg IV/IM initial for mildly agitated patients
5 mg IV/IM initial for more severely agitated patients
additional doses q5-10min; may titrate up to 10-15 mg prn
Pediatric Dose<3 years: Not established
3-12 years: 0.05-0.15 mg/kg/d divided/bid/tid
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; narrow-angle glaucoma, bone marrow suppression, severe cardiac or liver disease, severe hypotension, or subcortical brain damage; Parkinsonism
InteractionsMay increase TCA serum-concentrations and hypotensive action of antihypertensive agents; phenobarbital or carbamazepine may decrease effects; coadministration with anticholinergics may increase intraocular pressure; encephalopathylike syndrome associated with concurrent administration with lithium
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsSevere neurotoxicity manifesting as rigidity or inability to walk or talk may occur in patients with thyrotoxicosis also receiving antipsychotics; if IV/IM, monitor for hypotension; caution in CNS depression or cardiac disease; if history of seizures, benefits must outweigh risks; significant increase in body temperature may indicate intolerance to antipsychotics (discontinue if this occurs); do not use decanoate salt IV
Drug Name
Droperidol (Inapsine) -- Somewhat faster-acting and more sedating than haloperidol but more likely to cause hypotension.
May exert antipsychotic activity through dopaminergic system. Evidence suggests that it alters dopamine action in CNS.
Administer IV in small boluses and titrate to effect. IM route may also be used if IV access is not yet established.
Adult Dose2.5 mg IV initial for mildly agitated patients
5 mg IV initial for more severely agitated patients
Additional doses q5-10min; may titrate up to 20 mg prn
Pediatric Dose<12 years: Not established
>12 years: Administer as in adults
ContraindicationsDocumented hypersensitivity; Parkinsonism
InteractionsMay increase toxicity of CNS depressants
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsSome individuals are highly sensitive and may require only one initial dose; hypovolemic patients may experience hypotension; may decrease pulmonary arterial pressure; tardive dyskinesia in patients receiving droperidol is 40%; elderly persons may experience high rate of extrapyramidal reactions; life-threatening arrhythmias may occur
Drug Name
Diazepam (Valium) -- Administered IV. Additional doses are titrated to effect. Less effective than the butyrophenones in controlling agitation.
Adult Dose5 mg IV bolus; titrate upward to effect, giving additional drug q5-10min; in very severe cases, up to 50 mg may be required
Pediatric Dose0.1-0.2 mg/kg IV q15-20min
ContraindicationsDocumented hypersensitivity
InteractionsMay cause profound sedation with other CNS depressants
Pregnancy D - Unsafe in pregnancy
PrecautionsMonitor for excess CNS or respiratory depression with higher doses
Drug Name
Lorazepam (Ativan) -- Sedative hypnotic with short onset of effects and relatively long half-life.
Benzodiazepine of choice in the ED. Can be given PO or SL (for rapid effect in panic attack) and IM or IV (mixed in the same syringe with the antipsychotic). Has longer CNS effects than diazepam and is preferred over antipsychotics for treatment of psychosis secondary to acute intoxication with hallucinogens, cocaine, PCP, and stimulants. Can be used as adjunctive therapy in nonorganic acute psychosis in which DOC is a high potency antipsychotic.
If given IM, may take 30-60 min to observe desired effect.
Adult Dose1 mg IV bolus; may give additional doses q10-15min; not to exceed 8 mg
Pediatric Dose0.05-0.1 mg/kg IV over 1-2 min; may repeat, if needed
ContraindicationsDocumented hypersensitivity; preexisting CNS depression, hypotension, and narrow-angle glaucoma
InteractionsToxicity of benzodiazepines in CNS increases when used concurrently with alcohol, phenothiazines, barbiturates, and MAOIs
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsCaution in renal or hepatic impairment, myasthenia gravis, organic brain syndrome, or Parkinson disease; watch for excess CNS or respiratory depression with higher doses
Drug Name
Midazolam (Versed) -- Used as alternative in termination of refractory status epilepticus. Because water soluble, takes approximately 3 times longer than diazepam to peak EEG effects. Thus, clinician must wait 2-3 min to fully evaluate sedative effects before initiating procedure or repeating dose. Has twice the affinity for benzodiazepine receptors than diazepam. May be administered IM if unable to obtain vascular access.
Adult Dose0.01-0.05 mg/kg IV (usually 0.5-4 mg, up to 10 mg) slowly over several min; may repeat q10-15min until adequate response achieved
Pediatric Dose<32 weeks: 0.5 mcg/kg/min IV infusion>32 weeks: 1 mcg/kg/min IV infusion
Children: 0.05-0.2 mg/kg IV over 2-3 min, followed by 1-2 mcg/kg/min IV continuous infusion
Status epilepticus (refractory to standard therapy), >2 months and children: 0.15 mg/kg IV followed by continuous infusion of 1 mcg/kg/min IV, titrating dose upward q5min until seizures controlled
ContraindicationsDocumented hypersensitivity; preexisting hypotension, narrow-angle glaucoma, and sensitivity to propylene glycol (diluent)
InteractionsSedative effects may be antagonized by theophyllines; narcotics, cimetidine, ethanol, and erythromycin may accentuate sedative effects because of decreased clearance; reduce dose of thiopental by 15% when using together
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsCaution in congestive heart failure, pulmonary disease, renal impairment, hepatic failure, neuromuscular disease, hypotension, and patients >60 y; monitor for respiratory depression with high or repeated doses; consider lower dosages with organic brain syndrome, and patients who may have inhibition of benzodiazepine metabolism and clearance (eg, using nicotine, taking cimetidine)
Drug Category: Cardiovascular agents -- Used to control catecholamine-induced hypertension.
Drug Name
Labetalol (Normodyne, Trandate) -- Blocks beta1-, alpha-, and beta2-adrenergic receptor sites, decreasing blood pressure. When given IV, acts primarily as a beta-receptor antagonist.
Adult Dose20 mg IV over 2 min initial; may repeat 10 mg IV q5-10min until BP control is obtained; not to exceed 300 mg/dose
Pediatric DoseNot established
ContraindicationsDocumented hypersensitivity; cardiogenic shock, pulmonary edema, bradycardia, atrioventricular block, uncompensated congestive heart failure, reactive airway disease, and severe bradycardia
InteractionsDecreases effect of diuretics and increases toxicity of methotrexate, lithium, and salicylates; may diminish reflex tachycardia, resulting from nitroglycerin use, without interfering with hypotensive effects; cimetidine may increase levels in blood; glutethimide may decrease effects by inducing microsomal enzymes
Pregnancy C - Safety for use during pregnancy has not been established.
PrecautionsPregnancy D in second and third trimester; caution in impaired hepatic function; discontinue therapy if signs of liver dysfunction are present; in elderly patients, a lower response rate and higher incidence of toxicity may be observed
  FOLLOW-UP Section 8 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Further Inpatient Care:

Complications:

Prognosis:

Patient Education:

  MISCELLANEOUS Section 9 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page Click here to go to the next section in this topic
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

Medical/Legal Pitfalls:

  • Failure to diagnose and treat patients with methamphetamine toxicity if they have hyperthermia or rhabdomyolysis
  • Failure to obtain a head CT scan in patients with methamphetamine toxicity who present with mental status changes that do not normalize with pharmacologic treatment; thus, failing to diagnose an intracerebral hemorrhage
  • Failure to diagnose myocardial infarction or unstable angina in methamphetamine-intoxicated patients

Special Concerns:

  • Consider the possibility of methamphetamine or amphetamine toxicity in children who present with first-time seizures; several studies have noted amphetamine-positive drug screens in this patient population.
  • Healthcare personnel should be aware regarding blood-borne exposure and risk of HIV, hepatitis B, and hepatitis C.
  BIBLIOGRAPHY Section 10 of 10   Click here to go to the previous section in this topic Click here to go to the top of this page
Author Information Introduction Clinical Differentials Workup Treatment Medication Follow-up Miscellaneous Bibliography

  • Albertson TE, Walby WF, Derlet RW: Stimulant-induced pulmonary toxicity. Chest 1995 Oct; 108(4): 1140-9[Medline].
  • Bashour TT: Acute myocardial infarction resulting from amphetamine abuse: a spasm- thrombus interplay? Am Heart J 1994 Dec; 128(6 Pt 1): 1237-9[Medline].
  • Beebe DK, Walley E: Smokable methamphetamine ('ice'): an old drug in a different form. Am Fam Physician 1995 Feb 1; 51(2): 449-53[Medline].
  • Burton BT: Heavy metal and organic contaminants associated with illicit methamphetamine production. NIDA Res Monogr 1991; 115: 47-59[Medline].
  • Catanzarite VA, Stein DA: 'Crystal' and pregnancy--methamphetamine-associated maternal deaths. West J Med 1995 May; 162(5): 454-7[Medline].
  • Cherner M, Letendre S, Heaton RK: Hepatitis C augments cognitive deficits associated with HIV infection and methamphetamine. Neurology 2005; 64: 1343-47[Medline].
  • Conn C, Dawson M, Baker AT, et al: Identification of n-acetylmethamphetamine in a sample of illicitly synthesized methamphetamine. J Forensic Sci 1996 Jul; 41(4): 645-7[Medline].
  • Davis GG, Swalwell CI: Acute aortic dissections and ruptured berry aneurysms associated with methamphetamine abuse. J Forensic Sci 1994 Nov; 39(6): 1481-5[Medline].
  • Derlet RW, Albertson TE, Rice P: Protection against d-amphetamine toxicity. Am J Emerg Med 1990 Mar; 8(2): 105-8[Medline].
  • Derlet RW, Heischober B: Methamphetamine. Stimulant of the 1990s? West J Med 1990 Dec; 153(6): 625-8[Medline].
  • Derlet RW, Rice P, Horowitz BZ, Lord RV: Amphetamine toxicity: experience with 127 cases. J Emerg Med 1989 Mar-Apr; 7(2): 157-61[Medline].
  • Emonson DL, Vanderbeek RD: The use of amphetamines in U.S. Air Force tactical operations during Desert Shield and Storm. Aviat Space Environ Med 1995 Mar; 66(3): 260-3[Medline].
  • He SY, Matoba R, Fujitani N, et al: Cardiac muscle lesions associated with chronic administration of methamphetamine in rats. Am J Forensic Med Pathol 1996 Jun; 17(2): 155-62[Medline].
  • Katsumata S, Sato K, Kashiwade H, et al: Sudden death due presumably to internal use of methamphetamine. Forensic Sci Int 1993 Dec; 62(3): 209-15[Medline].
  • Logan BK: Methamphetamine and driving impairment. J Forensic Sci 1996 May; 41(3): 457-64[Medline].
  • MacKenzie RG, Heischober B: Methamphetamine. Pediatr Rev 1997 Sep; 18(9): 305-9[Medline].
  • Nestor TA, Tamamoto WI, Kam TH, Schultz T: Crystal methamphetamine-induced acute pulmonary edema: a case report. Hawaii Med J 1989 Nov; 48(11): 457-8, 460[Medline].
  • Ramamoorthy JD, Ramamoorthy S, Leibach FH, Ganapathy V: Human placental monoamine transporters as targets for amphetamines. Am J Obstet Gynecol 1995 Dec; 173(6): 1782-7[Medline].
  • Rhee KJ, Albertson TE, Douglas JC: Choreoathetoid disorder associated with amphetamine-like drugs. Am J Emerg Med 1988 Mar; 6(2): 131-3[Medline].
  • Richards JR, Derlet RW, Duncan DR: Methamphetamine toxicity: treatment with a benzodiazepine versus a butyrophenone. Eur J Emerg Med 1997 Sep; 4(3): 130-5[Medline].
  • Richards JR, Johnson EB, Stark RW, Derlet RW: Methamphetamine abuse and rhabdomyolysis in the ED: a 5-year study. Am J Emerg Med 1999 Nov; 17(7): 681-5[Medline].
  • Schermer CR, Wisner DH: Methamphetamine use in trauma patients: a population-based study. J Am Coll Surg 1999 Nov; 189(5): 442-9[Medline].
  • Stewart JL, Meeker JE: Fetal and infant deaths associated with maternal methamphetamine abuse. J Anal Toxicol 1997 Oct; 21(6): 515-7[Medline].
  • Turnipseed SD, Richards JR, Kirk JD: Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after methamphetamine use. J Emerg Med 2003 May; 24(4): 369-73[Medline].
  • Watts DJ, McCollester L: Methamphetamine-induced myocardial infarction with elevated troponin I. Am J Emerg Med 2006 Jan; 24(1): 132-4[Medline].

Toxicity, Methamphetamine excerpt